GEA
ROIV icon

Glen Eagle Advisors’s Roivant Sciences ROIV Stock Holding History

Glen Eagle Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-435
Closed -$4.9K – 1141
2025
Q2 		$4.9K Hold
435
– – ﹤0.01% 733
2025
Q1 		$4.39K Hold
435
– – ﹤0.01% 746
2024
Q4 		$5.15K Hold
435
– – ﹤0.01% 744
2024
Q3 		$5.02K Buy
+435
New +$4.95K ﹤0.01% 759

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Glen Eagle Advisors's ROIV Position: Q3 2025 in Review

Glen Eagle Advisors sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 435 shares — an estimated $4.9K sold.

Glen Eagle Advisors first reported a position in ROIV in Q3 2024 and held it in 4 quarters. The position peaked at $5.15K in Q4 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Glen Eagle Advisors reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Glen Eagle Advisors sold 435 Roivant Sciences shares in Q3 2025, an estimated $4.9K.
  • Glen Eagle Advisors first reported a position in Roivant Sciences in Q3 2024 and held it in 4 quarters.
  • Glen Eagle Advisors's Roivant Sciences position peaked at $5.15K in Q4 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Glen Eagle Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.